AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Adverum Biotechnologies Q2: ARTEMIS Phase 3 enrollment exceeds expectations.
ByAinvest
Tuesday, Aug 12, 2025 8:19 am ET1min read
• Adverum Biotechnologies reports Q2 2025 financial results • ARTEMIS Phase 3 trial enrollment exceeds expectations • Driven by retina specialist and patient enthusiasm • Enrollment completion expected in 1Q 2026 • Topline data anticipated in 1H 2027 • LUNA 2-year long-term follow-up data planned in 4Q 2025 • $10 million private placement with Frazier Life Sciences
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) reported its financial results for the second quarter of 2025, highlighting strong progress in its ARTEMIS Phase 3 trial for wet age-related macular degeneration (AMD). The company also announced a $10 million private placement with Frazier Life Sciences.The ARTEMIS Phase 3 trial, which is evaluating the company's gene therapy product candidate ixoberogene soroparvovec (Ixo-vec), has exceeded enrollment expectations. The trial is driven by robust interest from retina specialists and patients, with enrollment surpassing initial projections. The company expects to complete enrollment in the first quarter of 2026 and anticipates topline data in the first half of 2027 [1].
Adverum's president and CEO, Laurent Fischer, M.D., stated, "We are thrilled to report excellent progress in the ARTEMIS Phase 3 trial, with enrollment driven by robust interest from retina specialists and patients." He added, "We are well ahead of schedule, and momentum continues to build."
In addition to the ARTEMIS trial, Adverum plans to present two-year follow-up data from its LUNA Phase 2 study in the fourth quarter of 2025 [1]. The company also expects to initiate its AQUARIUS Phase 3 trial in the fourth quarter of 2025, pending funding availability [1].
Adverum's financial results for the second quarter of 2025 showed a net loss of $49.2 million, or $2.34 per basic and diluted share, compared to $30.5 million, or $1.46 per basic and diluted share for the same period in 2024. The company's cash, cash equivalents, and short-term investments were $44.4 million as of June 30, 2025, compared to $125.7 million as of December 31, 2024 [1].
Adverum also announced a $10 million private placement with Frazier Life Sciences, one of its largest investors. The transaction is expected to close on August 12, 2025, subject to customary closing conditions [1].
References:
[1] https://www.nasdaq.com/press-release/adverum-biotechnologies-reports-second-quarter-2025-financial-results-and-provides
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet